Abstract
During development of the cerebellum, a large number of molecular factors interact to produce an intricate brain structure. Many of these developmentally significant genes are members of signaling cascades implicated in the formation and growth of the embryonal brain tumor medulloblastoma. Genes controlling critical developmental pathways such as Hedgehog, Notch, Wnt, and Myc are known to be overexpressed and/or genetically altered in subsets of medulloblastoma. These pathways are also linked by their ability to induce or maintain stem-cell phenotypes in normal development. Their over-activation in tumors can lead to proliferation, invasion, altered metabolism, and evasion of treatment-induced cell death. The importance of these signaling cascades in medulloblastoma cells makes them attractive targets for therapeutic intervention. The development of therapeutic agents targeting these pathways may lead to improvement in patient survival and a reduction in the intensity of highly morbid radiation and chemotherapy that patients currently receive. In this review, we discuss a number of approaches to targeting these pathways in medulloblastoma.
Keywords: Non-genotoxic therapy, primitive neuroectodermal tumor, gamma secretase, tankyrase, glutamine, cyclopamine, itraconazole
Current Signal Transduction Therapy
Title:Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Volume: 8 Issue: 1
Author(s): Eric Raabe and Charles G. Eberhart
Affiliation:
Keywords: Non-genotoxic therapy, primitive neuroectodermal tumor, gamma secretase, tankyrase, glutamine, cyclopamine, itraconazole
Abstract: During development of the cerebellum, a large number of molecular factors interact to produce an intricate brain structure. Many of these developmentally significant genes are members of signaling cascades implicated in the formation and growth of the embryonal brain tumor medulloblastoma. Genes controlling critical developmental pathways such as Hedgehog, Notch, Wnt, and Myc are known to be overexpressed and/or genetically altered in subsets of medulloblastoma. These pathways are also linked by their ability to induce or maintain stem-cell phenotypes in normal development. Their over-activation in tumors can lead to proliferation, invasion, altered metabolism, and evasion of treatment-induced cell death. The importance of these signaling cascades in medulloblastoma cells makes them attractive targets for therapeutic intervention. The development of therapeutic agents targeting these pathways may lead to improvement in patient survival and a reduction in the intensity of highly morbid radiation and chemotherapy that patients currently receive. In this review, we discuss a number of approaches to targeting these pathways in medulloblastoma.
Export Options
About this article
Cite this article as:
Raabe Eric and G. Eberhart Charles, Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010008
DOI https://dx.doi.org/10.2174/1574362411308010008 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial:Tubulin-targeted Cancer Chemotherapeutics: Advances and Challenges
Current Topics in Medicinal Chemistry The Anterior Gradient-2 Pathway as a Model for Developing Peptide-Aptamer Anti-Cancer Drug Leads that Stimulate p53 Function
Current Chemical Biology Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin
Current Drug Targets Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Current Molecular Medicine Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets The Role of Stress Proteins in Prostate Cancer
Current Genomics Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets FADS1 is a Prognostic Biomarker in Bladder Cancer: A Study Based on TCGA Data
Combinatorial Chemistry & High Throughput Screening Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology